Canadian research suggests recommendations against screening for prostate cancer has led to a rise in the rates of stage 4 cases and less progress in mortality, even as other experts disagree and cite ...

Statistics show a clear spike in eight cancers in younger people, but that has brought a debate over whether many cases ever ...

Prostate cancer incidence is predicted to double to 2·9 million cases by 2040. Men diagnosed with clinically significant prostate cancer have many effective treatment options, but questions remain ...

Prostate cancer is still among the most prevalent cancers of men globally, but timely detection is everything. Over recent years, medical professionals have been emphasizing the key role of a simple ...

Official recommendations that discourage use of hotly debated screening test could be linked to increase, experts suggest ...

We have made important advancements in treatment, but are still being overwhelmed by the number of late-stage cases ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

Prostate cancer decision by UK National Screening Committee is expected to reject offering PSA test to Black men and those ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

A family history of prostate cancer has long been one of the few universally accepted risk factors for the disease. New findings now provide evidence that risk stratification based on family history ...